In this issue:
Prophylactic obinutuzumab & steroidrequiring chronic GVHD after allo-SCT
Venetoclax-fludarabine-melphalan conditioning in older patients with AML/MDS
Conditioning with briquilimab + nonmyeloablative fludarabine + TBI in older patients with AML/MDS
Bomedemstat in ET
PATHFINDER: avapritinib in advanced systemic mastocytosis
Sequential therapy with allo-HCT in AML patients aged ≥70
3-step dose-escalation with ropeginterferon alfa-2b in PV
Impaired renal function in symptomatic
Waldenström macroglobulinaemia
A switch from eltrombopag/romiplostim to avatrombopag in primary ITP
Allo-HSCT survival outcomes in Australia 1990–2023
Please login below to download this issue (PDF)